Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Trinity Innovation Bioventure Singapore (TIBS) is a licensed biomed venture capital fund established in 2018 and headquartered in Singapore. The firm is part of the Trinity Innovation Fund group and is dedicated to investing in the biomed sector, particularly within Asian markets. TIBS has built a reputation for its focus on innovation and value investment, aiming to identify and support emerging technologies in biotechnology.
The team at TIBS comprises seasoned professionals with extensive backgrounds in venture capital and biotechnology. The firm has received recognition for its efforts, including the title of 'Most Innovative Biomed Venture Capital Fund 2023 – Asia' from Wealth & Finance International. TIBS operates under the regulatory oversight of the Monetary Authority of Singapore (MAS), ensuring compliance and legitimacy in its investment activities.
TIBS concentrates its investments in the biomed sector, with a strong emphasis on innovation and value creation. The firm targets early-stage companies, from incubation through Series A funding, primarily in Asia, including key markets such as Singapore, Beijing, and Shanghai. TIBS seeks to identify emerging innovations and opportunities for new drug development, focusing on platform-driven biotech with breakthrough technologies.
The investment strategy is centered around companies that demonstrate differentiated scientific merit and commercial value, particularly those addressing unmet medical needs. TIBS aims to leverage its deep understanding of the Asian markets to foster growth in the biomed sector.
TIBS has invested in a range of biotech companies, showcasing its commitment to the biomed sector. Notable portfolio companies include:
These investments reflect TIBS's strategy of supporting innovative companies that are positioned to make significant impacts in the biomed field.
Jack Yin Zheng - Founding Partner; a veteran in venture capital with a background in pharmaceuticals and academia. He holds a PhD in Science from the National University of Singapore.
David Wang Xukun - Partner; brings 20 years of experience in biomedical research and pharmaceuticals. He holds a PhD in Biological Sciences and an MBA from the National University of Singapore.
Ivan Cao - Investment Partner; has 20 years of experience in private equity and founded a top-tier healthcare investment fund in China.
Langdon Wu - Managing Director; has a background in Fortune 500 companies and holds an Executive MBA from the National University of Singapore.
Thomas Keller - Scientific Advisor; an expert in drug discovery and preclinical development, holding a PhD in organic chemistry.
To pitch to TIBS, founders should use the contact form available on their website. It is important to include a comprehensive deck that outlines the business model, technology, and market potential. TIBS typically responds within a few weeks, and warm introductions are preferred but not mandatory.
In 2023, TIBS was awarded the title of 'Most Innovative Biomed Venture Capital Fund 2023 – Asia' by Wealth & Finance International, highlighting its impact in the biomed sector. Additionally, TIBS has been involved in significant financing rounds for its portfolio companies, including Tetris Therapeutics, which raised $15M in seed funding in May 2022.
TransThera Sciences, another portfolio company, successfully completed an IPO on the Hong Kong Stock Exchange in June 2025, marking a notable exit for TIBS and validating its investment strategy.
What are TIBS's investment criteria?
TIBS invests in early-stage biotech companies that demonstrate innovative technologies and address unmet medical needs. The firm looks for differentiated scientific merit and commercial viability in its portfolio companies.
How can founders apply or pitch to TIBS?
Founders can pitch their ideas through the official website at trinity-fund.com.sg. It is advisable to include a detailed business plan and information on the technology or product being developed.
What makes TIBS different from other venture capital firms?
TIBS's unique positioning lies in its deep understanding of the Asian markets, particularly the Singapore-China corridor, which bridges Southeast Asia and Greater China. This strategic focus allows TIBS to identify and capitalize on emerging opportunities in the biomed sector.
What is the geographic scope of TIBS's investments?
TIBS primarily invests in Asia, focusing on markets such as Singapore, Beijing, and Shanghai, while also maintaining some global exposure.
What is TIBS's approach to post-investment involvement?
TIBS actively supports its portfolio companies through mentorship and operational guidance, leveraging the extensive experience of its team in venture capital and biotechnology.
What is the fund size and check size for TIBS?
While specific fund size and check size details are not publicly disclosed, TIBS focuses on early-stage investments, typically ranging from incubation to Series A funding.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.